Parkinson’s disease
Neuroderm Ltd. focuses its clinical research on Parkinson’s disease, with particular attention to motor fluctuations and the management of daily ON/OFF periods in people living with advanced disease.
- Parkinson’s disease
- Motor fluctuations
- ON/OFF diary assessment
The sponsor’s studies are directed toward improving symptom control in patients experiencing variable response to treatment, with emphasis on maintaining functional time during the day.
Continuous subcutaneous infusion
Another major area of interest is continuous subcutaneous infusion for Parkinson’s disease, examining sustained delivery approaches intended to support steadier therapeutic exposure in advanced neurological care.
- Subcutaneous infusion
- Advanced Parkinson’s disease
- Continuous delivery therapy
Research in this domain reflects a therapeutic focus on non-oral administration routes for patients with complex treatment needs.
Safety and tolerability
Neuroderm Ltd. also places strong emphasis on the long-term safety, local tolerability, and systemic tolerability of therapies used in Parkinson’s disease, particularly for continuous infusion treatments.
- Long-term safety
- Local tolerability
- Systemic tolerability
This area supports the evaluation of treatment durability in patients requiring ongoing neurological management.
Comparison with oral therapy
The sponsor’s research landscape includes comparison of continuous subcutaneous treatment with oral therapy in Parkinson’s disease, highlighting interest in treatment alternatives for people whose symptoms are not adequately controlled by standard oral regimens.
- Oral treatment comparison
- Symptom control
- Advanced therapy options
These studies are centered on clinical outcomes relevant to daily functioning and treatment experience in neurological disease care.
